
Andrew Lloyd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11108149/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211056.	1.0	1
2	Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study. Medical Decision Making, 2021, 41, 209-221.	2.4	18
3	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	2.8	7
4	Estimation of the Quality-of-Life Impact of X-Linked Myotubular Myopathy. Journal of Neuromuscular Diseases, 2021, 8, 1047-1061.	2.6	4
5	Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. PharmacoEconomics - Open, 2021, , 1.	1.8	2
6	Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. PharmacoEconomics - Open, 2021, , 1.	1.8	2
7	Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 2021, , 1.	3.3	4
8	Authors' Response to Comment on "Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study― Medical Decision Making, 2021, , 0272989X2110622.	2.4	1
9	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health and Quality of Life Outcomes, 2020, 18, 310.	2.4	25
10	Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. Current Medical Research and Opinion, 2020, 36, 609-611.	1.9	8
11	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. Journal of Patient-Reported Outcomes, 2020, 4, 22.	1.9	6
12	Estimation of impact of <i>RPE65-</i> mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. British Journal of Ophthalmology, 2019, 103, 1610-1614.	3.9	38
13	Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?. Value in Health, 2019, 22, 62-68.	0.3	45
14	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2019, 22, 267-275.	0.3	98
15	The EQ-5D and the EuroQol Group. Value in Health, 2019, 22, 21-22.	0.3	18
16	Disutility Study for Adult Patients with Moderate to Severe Crohn's Disease. Journal of Health Economics and Outcomes Research, 2019, 6, 47-60.	1.2	6
17	EQ-5D: Moving from Three Levels to Five. Value in Health, 2018, 21, 57-58.	0.3	11
18	Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. Clinical Therapeutics, 2018, 40, 1878-1893.e1.	2.5	11

ANDREW LLOYD

#	Article	IF	CITATIONS
19	Gains in health utility associated with urinary catheter innovations. Medical Devices: Evidence and Research, 2018, Volume 11, 345-351.	0.8	4
20	Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectrums, 2017, 22, 31-40.	1.2	15
21	The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. Quality of Life Research, 2017, 26, 1879-1885.	3.1	38
22	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health, 2016, 19, 704-719.	0.3	101
23	Patient preferences and willingness to pay for innovations in intermittent self-catheters. Patient Preference and Adherence, 2015, 9, 381.	1.8	17
24	Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Preference and Adherence, 2015, 9, 1561.	1.8	11
25	Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia and Lymphoma, 2015, 56, 1839-1845.	1.3	23
26	Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. European Child and Adolescent Psychiatry, 2014, 23, 1189-1200.	4.7	28
27	Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoLâ,,¢). Quality of Life Research, 2014, 23, 449-458.	3.1	8
28	A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems. Quality of Life Research, 2013, 22, 2237-2243.	3.1	36
29	Elicitation of health state utilities in soft tissue sarcoma. Quality of Life Research, 2013, 22, 1697-1706.	3.1	21
30	Developing the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approach. Quality of Life Research, 2013, 22, 885-890.	3.1	66
31	One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. European Journal of Health Economics, 2013, 14, 65-73.	2.8	23
32	Development of a Disease-Specific Version of the EQ-5D-5L for Use in Patients Suffering from Psoriasis: Lessons Learned from a Feasibility Study in the UK. Value in Health, 2013, 16, 1156-1162.	0.3	68
33	Willingness to Pay for Obesity Pharmacotherapy. Obesity, 2012, 20, 2019-2026.	3.0	15
34	Androgen Deprivation Therapy for Prostate Cancer Prevention: What Impact Do Related Adverse Events Have on Quality of Life?. Health Outcomes Research in Medicine, 2012, 3, e169-e180.	0.6	3
35	Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. Health Outcomes Research in Medicine, 2012, 3, e153-e167.	0.6	4
36	Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. Value in Health, 2012, 15, 708-715.	0.3	1,381

ANDREW LLOYD

#	Article	IF	CITATIONS
37	A Systematic Review and Critical Assessment of Health State Utilities. Pharmacoeconomics, 2012, 30, 1133-1143.	3.3	8
38	Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations. Patient, 2011, 4, 247-257.	2.7	16
39	Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 2011, 14, 403-413.	0.3	1,342
40	Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus. Clinical Therapeutics, 2011, 33, 1258-1267.	2.5	31
41	Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences. International Journal of Technology Assessment in Health Care, 2011, 27, 215-223.	0.5	17
42	Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 2010, 26, 1091-1096.	1.9	52
43	Reimbursement agency requirements for health related quality-of-life data: a case study. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 527-537.	1.4	9
44	Preferences and utilities for the symptoms of moderate to severe allergic asthma. European Journal of Health Economics, 2008, 9, 275-284.	2.8	17
45	Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations. Value in Health, 2008, 11, 1178-1185.	0.3	30
46	How Does Patients' Quality of Life Guide Their Preferences Regarding Aspects of Asthma Therapy?. Patient, 2008, 1, 309-316.	2.7	6
47	How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology. Patient, 2008, 1, 309-16.	2.7	7
48	Patient-reported outcomes measurements in epilepsy. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 373-384.	1.4	9
49	The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 22-27.	2.3	126
50	Patient preferences for asthma therapy: a discrete choice experiment. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 241-248.	2.3	25
51	Health Utilities Using the EQ-5D in Studies of Cancer. Pharmacoeconomics, 2007, 25, 365-384.	3.3	232
52	Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. Journal of Medical Economics, 2007, 10, 285-296.	2.1	30
53	Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. International Psychogeriatrics, 2006, 18, 151-162.	1.0	104
54	The Importance of Drug Adverse Effects Compared with Seizure Control for People with Epilepsy. Pharmacoeconomics, 2005, 23, 1167-1181.	3.3	46